Certara operates globally, serving over 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. The company's core offerings include its Simcyp and Phoenix biosimulation platforms, which model pharmacokinetics and pharmacodynamics to predict how drugs will behave in the human body. In addition to software, Certara provides technology-enabled services such as regulatory writing, clinical pharmacology consulting, and market access strategies. By integrating quantitative science with proprietary software, the company helps clients navigate complex regulatory pathways and optimize clinical trial designs. Certara's platforms are widely adopted, with its technology utilized in the development of a vast majority of novel drugs approved by the FDA in recent years.
